The FDA paused a controversial policy to proactively release drug rejection letters while it moves to formalize the underlying approach. The halt follows a citizen’s petition from an unnamed pharma company filed earlier this year, underscoring the policy’s sensitivity for applicants and how procedural transparency is being reworked.